EXOSURF NEONATAL
LOE ApproachingNDAINTRATRACHEALFOR SUSPENSIONPriority Review
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXOSURF NEONATAL is an intratracheal suspension approved in 1990 for neonatal respiratory distress syndrome. It is a synthetic pulmonary surfactant designed to replace deficient endogenous surfactant in premature infants. The drug works by reducing surface tension in the alveoli, improving lung compliance and gas exchange.
LOE Approaching
Late-stage product with declining market exclusivity; commercial teams likely focused on portfolio transition rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EXOSURF NEONATAL offers limited career growth opportunities due to its mature lifecycle stage and approaching loss of exclusivity. Roles on this product are primarily focused on managing decline, maintaining compliance, and optimizing remaining revenue rather than driving innovation or expansion.
Brand ManagerMarket Access Manager
Worked on EXOSURF NEONATAL at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.